Abstract
One of the most neglected disease is the Sleeping sickness or Human African Trypanosomiasis (HAT), which is mostly restricted to poor regions of Africa. The disease is caused by parasitic infection with Trypanosoma brucei (T. brucei), and is acquired through the bite of the tsetse fly. In the first stage of the disease, the parasite is in the blood, but in stage 2, the infective form reaches the brain, causing great weakness and death. The few existing drugs against this infection, are highly toxic, and can cause the emergence of resistant forms of the parasite. Also, these drugs are not readily available. New drugs are needed. Many researchers are investigating new enzyme targets for the parasite, searching for more efficient and selective inhibitors that are capable to cause the parasite death with less toxicity to the host. Trypanothione reductase, farnesyl diphosphate synthase, 6-phospho-gluconate dehydrogenase, and UDP 4'-galactose epimerase are some of the enzymes involved in the studies reported on this review. In addition, we have applied ligandbased- virtual screening, using Random Forest associated with structure-based-virtual screening (docking), to a small dataset of 225 alkaloids from the Menispermaceae family (in-house data bank). The aim of this study is to select structures with potential inhibitory activity against trypanothione reductase from Trypanosoma brucei. The computer-aided drug design study selected certain alkaloids that might be worth further investigation.
Keywords: Sleeping sickness, T. brucei, enzyme, docking, trypanothione reductase, target.
Graphical Abstract
Current Protein & Peptide Science
Title:Enzymatic Targets in Trypanosoma brucei
Volume: 17 Issue: 3
Author(s): Luciana Scotti, Francisco J.B. Mendonça, Marcelo S. da Silva and Marcus T. Scotti
Affiliation:
Keywords: Sleeping sickness, T. brucei, enzyme, docking, trypanothione reductase, target.
Abstract: One of the most neglected disease is the Sleeping sickness or Human African Trypanosomiasis (HAT), which is mostly restricted to poor regions of Africa. The disease is caused by parasitic infection with Trypanosoma brucei (T. brucei), and is acquired through the bite of the tsetse fly. In the first stage of the disease, the parasite is in the blood, but in stage 2, the infective form reaches the brain, causing great weakness and death. The few existing drugs against this infection, are highly toxic, and can cause the emergence of resistant forms of the parasite. Also, these drugs are not readily available. New drugs are needed. Many researchers are investigating new enzyme targets for the parasite, searching for more efficient and selective inhibitors that are capable to cause the parasite death with less toxicity to the host. Trypanothione reductase, farnesyl diphosphate synthase, 6-phospho-gluconate dehydrogenase, and UDP 4'-galactose epimerase are some of the enzymes involved in the studies reported on this review. In addition, we have applied ligandbased- virtual screening, using Random Forest associated with structure-based-virtual screening (docking), to a small dataset of 225 alkaloids from the Menispermaceae family (in-house data bank). The aim of this study is to select structures with potential inhibitory activity against trypanothione reductase from Trypanosoma brucei. The computer-aided drug design study selected certain alkaloids that might be worth further investigation.
Export Options
About this article
Cite this article as:
Scotti Luciana, J.B. Mendonça Francisco, S. da Silva Marcelo and T. Scotti Marcus, Enzymatic Targets in Trypanosoma brucei, Current Protein & Peptide Science 2016; 17 (3) . https://dx.doi.org/10.2174/1389203717999160226173754
DOI https://dx.doi.org/10.2174/1389203717999160226173754 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Novel NaV1.7 Antagonists Using High Throughput Screening Platforms
Combinatorial Chemistry & High Throughput Screening Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Hydroxycarbazoles as Starting Materials in Organic Syntheses
Current Organic Synthesis Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design Late Sodium Current is a New Therapeutic Target to Improve Contractility and Rhythm in Failing Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes
Current Cardiology Reviews A Comprehensive Review on the Ethnobotany, Phytochemistry, Pharmacology, and Toxicology of <i>Mentha aquatic</i> L (water mint) as a Wild Shallow Vegetable
Current Pharmaceutical Design Passive Smoking, Endothelial Dysfunction and Related Markers in Healthy Individuals: An Update
Current Hypertension Reviews New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery
Current Vascular Pharmacology Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery Biomarkers for Diagnosing and Staging of Fabry Disease
Current Medicinal Chemistry A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Advances in Catheter Ablation: Atrial Fibrillation Ablation in Patients With Mitral Mechanical Prosthetic Valve
Current Cardiology Reviews Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety